Vivasc Therapeutics is built upon the proprietary Cardiac Targeting Peptide (CTP) platform technology.
CTP is a synthetic, non-naturally occurring peptide that acts as a novel vector to target the heart and has demonstrated ability to transduce:
- Normal mouse hearts in vivo (peak uptake at 15 minutes after injection)
- Explanted human heart tissue
- Human derived iPSC beating cardiomyocytes
CTP demonstrates robust transduction of normal cardiomyocytes and sparing of fibroblasts present in adjacent scar tissue. To date, CTP conjugates have transduced cardiomyocytes carrying intact cargo as diverse as nucleic acids, radioisotopes, therapeutics, and other peptides.